유바이오로직스

206650KOSDAQ

70.6 / 100

Reference Date: 2026-09-08

Financial Score31.5 / 40

News Sentiment20.1 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

YuBioLogics, established in 2010, is a biotech company specializing in vaccine development and supply, as well as CRMO services. It supplies cholera vaccines to UNICEF, achieving sales of 65.4 billion KRW in 2023, with continued growth driven by increasing global cholera outbreaks. The company aims to expand its product line to include typhoid and meningitis vaccines, targeting global market leadership.

Number of Employees

397people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.65Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

1.81Industry Average 1.201.0Point

1.5x industry avg (risky)

ROE

26.85Industry Average 8.007.0Point

3.4x industry avg (excellent)

Debt Ratio

13.20Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲46.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲211.3% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

14 totalPositive 13Neutral 0Negative 1Average Sentiment Score 80.4

Positive
콜레라 백신 '긴급→예방접종' 확대…유바이오로직스 공급 주목
유바이오로직스의 콜레라 백신 유비콜-S 공급 확대로 예방접종 확대에 기여, 긍정적 영향 예상.
Positive
유바이오로직스, 글로벌 콜레라 백신 수요 지속…공급 역할 부각
유바이오로직스는 글로벌 콜레라 백신 수요 증가로 인해 공급 역할이 강조되어 긍정적인 시장 반응을 얻고 있다.
Positive
유바이오로직스, 알츠하이머 치료백신 개발 본격화
유바이오로직스가 알츠하이머 치료백신 개발에 대한 투자를 확대함으로써 긍정적인 성장 동력을 확보했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 8,620Won52-week high 16,20052-week low 7,390

1-month return3.0Point

1m -0.81% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0

Neutral[기재정정]타법인주식및출자증권취득결정2026-08-26
Neutral신탁계약해지결과보고서2026-08-24
Neutral주식소각결정2026-08-21
Positive주요사항보고서(자기주식취득신탁계약해지결정)2026-08-21
Neutral투자판단관련주요경영사항(임상시험계획승인신청) (알츠하이머병 대응 백신 PADIVAX의 제1상 임상시험계획승인 신청(IND))2026-08-18